Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CAMPath and BELimumab for the Induction of Donor Specific Humoral Transplant Tolerance in Sensitized Kidney Transplant Recipients To Improve Long-Term Allograft Survival

Trial Profile

CAMPath and BELimumab for the Induction of Donor Specific Humoral Transplant Tolerance in Sensitized Kidney Transplant Recipients To Improve Long-Term Allograft Survival

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belimumab (Primary) ; Alemtuzumab; Mycophenolic acid; Steroids; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms CAMPBEL
  • Most Recent Events

    • 15 Apr 2019 Planned initiation date changed from 15 Mar 2019 to 17 Apr 2019.
    • 18 Mar 2019 Planned initiation date (estimated date of first participant enrollement) changed from 15 Mar 2019 to 1 Apr 2019.
    • 08 Mar 2019 Planned initiation date (estimated date of first participant enrollement) changed from 5 Mar 2019 to 15 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top